224PD - Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
- Resource Type
- Abstract
- Source
- In
Annals of Oncology 1 October 2016 27 Supplement 6:vi68-vi68 - Subject
- Language
- ISSN
- 0923-7534